These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
96 related articles for article (PubMed ID: 17506043)
21. Multivalency: the hallmark of antibodies used for optimization of tumor targeting by design. Deyev SM; Lebedenko EN Bioessays; 2008 Sep; 30(9):904-18. PubMed ID: 18693269 [TBL] [Abstract][Full Text] [Related]
22. [Bispecific antibodies in hematology and oncology]. Repp R; Valerius T; Bargou R Internist (Berl); 2001 Jun; 42(6):854-9. PubMed ID: 11449632 [No Abstract] [Full Text] [Related]
23. Target-dependent T-cell activation by coligation with a PSMA x CD3 diabody induces lysis of prostate cancer cells. Bühler P; Molnar E; Dopfer EP; Wolf P; Gierschner D; Wetterauer U; Schamel WW; Elsässer-Beile U J Immunother; 2009; 32(6):565-73. PubMed ID: 19483653 [TBL] [Abstract][Full Text] [Related]
24. Bispecific antibodies poised to deliver wave of cancer therapies. Sheridan C Nat Biotechnol; 2021 Mar; 39(3):251-254. PubMed ID: 33692520 [No Abstract] [Full Text] [Related]
25. Clinical perspectives of bispecific antibodies in cancer. de Gast GC; van de Winkel JG; Bast BE Cancer Immunol Immunother; 1997; 45(3-4):121-3. PubMed ID: 9435853 [No Abstract] [Full Text] [Related]
27. Radiocurability by targeting tumor necrosis factor-alpha using a bispecific antibody in carcinoembryonic antigen transgenic mice. Larbouret C; Robert B; Linard C; Teulon I; Gourgou S; Bibeau F; Martineau P; Santoro L; Pouget JP; Pelegrin A; Azria D Int J Radiat Oncol Biol Phys; 2007 Nov; 69(4):1231-7. PubMed ID: 17967312 [TBL] [Abstract][Full Text] [Related]
28. Functional humanization of an anti-CD16 Fab fragment: obstacles of switching from murine {lambda} to human {lambda} or {kappa} light chains. Schlapschy M; Fogarasi M; Gruber H; Gresch O; Schäfer C; Aguib Y; Skerra A Protein Eng Des Sel; 2009 Mar; 22(3):175-88. PubMed ID: 19022801 [TBL] [Abstract][Full Text] [Related]
29. Catumaxomab, a rat/murine hybrid trifunctional bispecific monoclonal antibody for the treatment of cancer. Shen J; Zhu Z Curr Opin Mol Ther; 2008 Jun; 10(3):273-84. PubMed ID: 18535935 [TBL] [Abstract][Full Text] [Related]
30. Boehringer splashes out on bispecific antibody platforms. Moran N Nat Biotechnol; 2011 Jan; 29(1):5-6. PubMed ID: 21221079 [No Abstract] [Full Text] [Related]
31. Monospecific and bispecific antibodies against E. coli O157 for diagnostics. Guttikonda S; Tang XL; Yang BM; Armstrong GD; Suresh MR J Immunol Methods; 2007 Oct; 327(1-2):1-9. PubMed ID: 17804009 [TBL] [Abstract][Full Text] [Related]
32. [Construction history of bispecific antibodies and overview of its application for cancer immunotherapy]. Asano R Seikagaku; 2005 Dec; 77(12):1497-501. PubMed ID: 16440753 [No Abstract] [Full Text] [Related]
38. DARPins as bispecific receptor antagonists analyzed for immunoglobulin E receptor blockage. Eggel A; Baumann MJ; Amstutz P; Stadler BM; Vogel M J Mol Biol; 2009 Oct; 393(3):598-607. PubMed ID: 19683003 [TBL] [Abstract][Full Text] [Related]
39. A divalent hapten-peptide induces apoptosis in human non hodgkin lymphoma cell lines targeted by anti-CD20xanti-hapten bispecific antibodies. Brard PY; Karacay H; Stein R; Sharkey RM; Mattes MJ; Chang CH; Rossi EA; McBride WJ; Goldenberg DM Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5564s-5571s. PubMed ID: 17875790 [TBL] [Abstract][Full Text] [Related]
40. Targeting solid tumors via T cell receptor complementarity-determining region 3delta in an engineered antibody. Wang Z; Zhang T; Hu H; Zhang H; Yang Z; Cui L; He W Cancer Lett; 2008 Dec; 272(2):242-52. PubMed ID: 18782650 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]